A Study of EDG-7500 in Healthy Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Subjects
In brief
The purposes of this Phase 1 study of EDG-7500 are to: 1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-7500 in the blood is similar for the suspension and tablet forms of EDG-7500 in healthy adults Participants will receive a single or multiple doses of EDG-7500 or a placebo by mouth.
Key facts
- Study ID
- NCT06011317
- Run by
- Edgewise Therapeutics, Inc.
- People needed
- 84
- Starts
- 2023-08-14
- Expected to finish
- 2024-06-20
- Last updated by the study team
- 2024-07-16
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Willing and able to give informed consent and follow all study procedures and requirements.
- Healthy male or nonpregnant female, ages ≥ 18 to < 60 years.
- Body mass index (BMI) ≥ 18 to < 35 kg/m2; weight ≥ 55 kg at Screening.
- Absence of important health problems and essentially normal physical examination, normal laboratory screening tests, and normal electrocardiogram (ECG) with QTcF ≤ 450 ms.
You may not qualify if…
- Evidence of clinically significant abnormalities or disease.
- Unless permitted by protocol, use of any prescription medication ≤ 4 weeks or investigational medication ≤ 12 weeks or ≤ 5 half-lives (whichever is longer) of dosing. Use of any non-prescription medication or herbal/nutritional supplement ≤ 5 days prior to dosing.
- Donation or loss of > 1 unit (450 mL) of blood ≤ 1 month prior to dosing.
- Females: nursing, lactating, or pregnant.
- Females: breast implants.
- Use of nicotine-containing products in the last 6 months prior to dosing.
- History of substance abuse or dependency or history of recreational drug use. Alcohol consumption > 14 drinks per week for males (7 for females). Positive screen for drugs of abuse or alcohol or cotinine test at Screening or Admission.
- Additional protocol defined inclusion/exclusion criteria may apply.
Where it is running
- Celerion — Tempe, Arizona, United States
- Celerion — Lincoln, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.